HIV Status Disclosure and Retention in Care in HIV-Infected Adolescents on Antiretroviral Therapy (ART) in West Africa

Elise Arrive\textsuperscript{1,2,}\textsuperscript{*}, Fatoumata Dicko\textsuperscript{3}, Hind Amghar\textsuperscript{1}, Addi Edmond Aka\textsuperscript{4}, H\textuml{e}l\textuml{e}ne Dior\textsuperscript{5}, Belinda Bouah\textsuperscript{6}, Mariam Traor\textuml{e}\textsuperscript{3}, Patricia Ogbo\textsuperscript{7}, Hortense Aka Dago-Akribi\textsuperscript{4}, Tannah Kassi F. Ebo\textsuperscript{6}, Kouadio Kouakou\textsuperscript{7}, Haby Signate Sy\textsuperscript{5}, Ahmadou Alioum\textsuperscript{1,2}, Fran\textuml{c}ois Dabis\textsuperscript{1,2}, Didier Koumavi Ekouevi\textsuperscript{2,8}, Val\textuml{e}r\textuml{a}ne Leroy\textsuperscript{1,2} for the Pediatric IeDEA West Africa Working Group\textsuperscript{†}

Abstract

Objective: We assessed the effect of HIV status disclosure on retention in care from initiation of antiretroviral therapy (ART) among HIV-infected children aged 10 years or more in Cote d’Ivoire, Mali and Senegal.

Methods: Multi-centre cohort study within five paediatric clinics participating in the IeDEA West Africa collaboration. HIV-infected patients were included in this study if they met the following inclusion criteria: aged 10–21 years while on ART; having initiated ART\textsuperscript{*} \textsuperscript{200 days before the closure date of the clinic database; followed \textsuperscript{a} \textsuperscript{\textsuperscript{15 days from ART initiation in clinics with \textsuperscript{\textsuperscript{\textsuperscript{10 adolescents enrolled. Routine follow-up data were merged with those collected through a standardized ad hoc questionnaire on awareness of HIV status. Probability of retention (no death or loss-to-follow-up) was estimated with Kaplan-Meier method. Cox proportional hazard model with date of ART initiation as origin and a delayed entry at date of 10th birthday was used to identify factors associated with death or loss-to-follow-up.

Results: 650 adolescents were available for this analysis. Characteristics at ART initiation were: median age of 10.4 years; median CD4 count of 224 cells/mm\textsuperscript{3} (47% with severe immunosuppression), 48% CDC stage C/WHO stage 3/4. The median follow-up on ART after the age of 10 was 23.3 months; 187 adolescents (28.8%) knew their HIV status. The overall probability of retention at 36 months after ART initiation was 74.6% (95% confidence interval [CI]: 70.5–79.0) and was higher for those disclosed compared to those not: adjusted hazard ratio for the risk of being death or loss-to-follow-up = 0.23 (95% CI: 0.13–0.39).

Conclusion: About 2/3 of HIV-infected adolescents on ART were not aware of their HIV status in these ART clinics in West Africa but disclosed HIV status improved retention in care. The disclosure process should be thus systematically encouraged and organized in adolescent populations.

Citation: Arrive E, Dicko F, Amghar H, Aka AE, Dior H, et al. (2012) HIV Status Disclosure and Retention in Care in HIV-Infected Adolescents on Antiretroviral Therapy (ART) in West Africa. PLoS ONE 7(3): e33690. doi:10.1371/journal.pone.0033690

Editor: Sten H. Vermund, Vanderbilt University, United States of America

Received October 19, 2011; Accepted February 19, 2012; Published March 21, 2012

Copyright: © 2012 Arrive et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The International epidemiological Database to Evaluate AIDS in West Africa (IeDEA West Africa) is supported by: the National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (grant no. 5U01AI069919-05). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: elise.arrive@isped.u-bordeaux2.fr
† Membership of the IeDEA West Africa Pediatric Working Group is provided in the Acknowledgments.

Introduction

In West Africa, children infected with HIV through mother-to-child transmission, once diagnosed and in care, live longer and reach adolescence, because of greater access to antiretroviral therapy (ART) drugs observed in West Africa in the past decade [1,2]. Adolescence is characterized by remarkable physical, mental and social changes and difficulties. In addition, adolescents, starting sexual activity are at high risk of HIV acquisition and transmission in areas of generalized epidemic [2].

Emotional and behavioural disorders have been described in Africa throughout adolescence. Musisi et al reported that, among 82 Ugandan HIV-infected adolescents, 98% were orphans, 51% reported psychological distress and 17% attempted suicide [3]. In a study in Zambia, about 40% of 127 HIV-infected adolescents reported mental health problems [4].
Virological failure has also been observed among adolescents [5,6,7] such as in a US series where it was observed in 67% of 154 adolescents, mainly associated with the lack of adherence and suboptimal ART use [8]. Treatment adherence may be one of the critical issues for therapeutic long-term success in adolescents. Problems of adherence were indeed noticed, not only in an American study, in 40% out of 396 adolescents [9], but also in Southern Africa in more than 60% of the adolescents surveyed [5].

Disclosed HIV status has been identified as one of the factors associated with better adherence [10,11]. However, the prevalence of disclosure in children and adolescents varies by setting and according to the age of the patients, from 13 to 60% in children between 5 to 17 years from Asia or Southern-Eastern Africa [4,12,13,14,15,16,17,18,19]. While also essential for the secondary prevention of HIV transmission, disclosure for adolescents may accentuate emotional and behavioural disorders, familial conflicts or social stigma perception and may thus jeopardize confidentiality [20,21]. HIV status disclosure of youths represents a challenge for the family and for medical staff [22,23,24].

The disclosure process in adolescents is poorly documented outside Southern Africa and it is not known whether it may influence their clinical response to ART. The main objectives of this study were thus (1) to estimate the frequency of HIV disclosure in an adolescent population in West African settings; (2) to assess the effect of disclosed HIV status to HIV-infected adolescents on ART clinical outcomes (death and loss-to-follow-up).

Methods

Ethics statement

The IeDEA West Africa collaboration project received ethical approval from the Bordeaux University Hospital Institutional Review Board. A waiver for informed consent was given as this data was collected from routine patients' charts.

Study design

We conducted a retrospective study nested in a multi-centre prospective cohort network of paediatric clinics participating in the International epidemiological database to Evaluate AIDS (IeDEA) West Africa collaboration (http://mereva.net/iedea). This collaboration was initiated in 2006 and currently involves 11 pediatric HIV/AIDS clinics spread over seven countries: Benin, Burkina Faso, Côte d’Ivoire, Ghana, Mali, Senegal and Togo [25]. However, as the centers from Côte d’Ivoire, Mali and Senegal followed-up about 90% of all adolescents from this collaboration, the present study was therefore restricted to these countries, including three centers in Abidjan, Côte d’Ivoire (the pediatric ward of the Teaching Hospital of Yopougon, the Centre Intégré de Recherches Biocliniques (CIRBA), the Centre de Prise en charge de Recherche et de Formation (CePRéF); the pediatric ward of Gabriel Touré Hospital in Bamako, Mali and the pediatric ward of Albert Royer Hospital in Dakar, Senegal.

Study sample

In each pediatric clinic participating in the IeDEA West Africa collaboration, clinical forms were available for recording HIV activities and an electronic database for data entry. All HIV-infected children (positive viral load test at <18 months or positive serology at ≥18 months) aged <21 years with documented gender and antiretroviral drug regimen were included. These HIV-infected children were typically seen in clinics at least every three months, and their CD4 counts were measured twice a year to monitor their immunological response to ART. Routine viral load monitoring was not available in most sites.

The inclusion criteria in the present study were:

- Aged 10–21 years during follow-up while on ART
- Follow-up in a paediatric clinic with ≥10 adolescents in care
- Having initiated ART ≥200 days before the closure date of the local database
- Followed-up ≥15 days from ART initiation.

Adolescence is usually defined by the World Health Organization (WHO) [26] as the period between childhood and adult age, from 10 to 19 years. In our study we extended the age upper limit to 21 years as this is the age of legal majority in Côte d’Ivoire (18 in the other countries).

Strategies of HIV disclosure varied according to sites: in Dakar, focus group and patient education were proposed. In Bamako, a monthly follow-up for the adolescent and his/her parents was conducted by a dedicated physician. The three sites from Abidjan had a team of psychologists providing psychological support to the children and the caregivers, not only for disclosure, but also for adherence for instance. However, none of the sites had developed local guidelines.

Data collection

In the context of the IeDEA West Africa collaboration, baseline and follow-up data were recorded in the local databases computerized in the participating clinics and merged together in a larger database (Microsoft Office Access 2003). All data were anonymized using a unique, confidential identification number.

The following data from patients meeting inclusion criteria were extracted from the pediatric central database:

- Demographic data: date of birth, gender
- ART regimen: type and date of initiation
- Biological and clinical data at treatment initiation (or 200 days before): CD4 cell count and CD4 percentage, haemoglobin, CDC and WHO clinical stage
- Outcomes: Transfer out, death, CD4 CD4 cell count and CD4 percentage and dates of events

A standardized form was created to extract study specific data from the medical, psychological and social charts available in the patient's files. This form was prepared based on literature review and discussions between the investigators and the staff in charge of disclosure in each clinic. The questionnaire was tested in Abidjan to reach a final version before full implementation in May 2010. It included the following information:

- Own HIV status disclosed to the adolescent ("Is the adolescent informed about his/her HIV status?"), and if so,
  - date of disclosure
  - Persons involved: physician, social worker, psychologist…
  - Conditions of disclosure: planned or not, timing (before or after ART initiation)
  - Immediate reaction to disclosure
- Individual situation at disclosure or at closure date: living, schooling

The questionnaire was completed by physicians, psychologists or social workers involved in each clinic. Data specific to the study were computerized on each site using Epi-Info software version 3.3.2 and then were merged in the IeDEA West Africa central office in Bordeaux.
Statistical analysis

To compare the characteristics of adolescents included or not in the analyses, as well as of those with disclosed HIV status or not, Fisher and Chi-square tests and Kruskal-Wallis tests were used for qualitative variables and quantitative variables, respectively.

Probability of death, loss-to-follow-up, and retention in HIV care (patients neither dead nor lost-to-follow-up) was estimated with the Kaplan-Meier method overall and according to the HIV disclosure status. Loss-to-follow-up was defined as the last contact before 21 years of age recorded ≥200 days before the closure date of local database, with no mention of transfer out or death.

The end point was defined as the date of death, loss-to-follow-up, 21st birthday or last contact before the closure date of the database (04/01/2008 for the Teaching Hospital of Yopougon, 05/11/2008 for the CIRBA, 05/11/2008 for the CePRF, 20/12/2008 for the Bamako Hospital, 19/06/2009 for the Dakar Hospital.

To assess factors associated with these risk functions, Cox model was used, with date of ART initiation as origin, censoring at the closure dates of the local databases and with delayed entry at date of 10th birthday for those who initiated ART before 10. All analyses used the center as a cluster variable, taking into account the correlation of the observations within a same center. Missing data (MD) were treated as specific categories except for the variable of interest (disclosed HIV status). Patients with missing data on this variable were excluded.

All analyses were performed with SAS software 8.2 (USA). All p-values were two-tailed. A p-value < 0.05 was considered as statistically significant. Variables with a p < 0.20 in univariate models were examined in multivariate models and selected thereafter using a backward stepwise procedure. Hazard ratios (HR) and their 95% confidence intervals (CIs) were produced.

Results

Sample description

The inclusion criteria were met by 669 adolescents (Figure 1) from the five centers selected. Nineteen had missing data on HIV disclosure status and were described separately. Thus, 650 adolescents remained in the analysis, representing 93.8% of the selected population (Figure 1). They had a median age at ART initiation of 10.4 years, a median CD4 count of 224 cells/mm³ (46.9% with severe immunosuppression; i.e. CD4 <200 cells/mm³; 68 with MD), a median haemoglobin of 10.0 g/dL (4.8% with severe anaemia; i.e. blood haemoglobin < 6.9 g/dL; 93 MD) and 277 (48.1%) were stage 3 or 4/C at ART initiation (73 MD) (Table 1). Most of them (n = 447; 68.8%) started with a non nucleosidic (NNRTI)-based ART regimen.

About 55% of the adolescents (n = 360) started ART after the age of ten. Over a median 35.8 months follow-up period from ART initiation (23.3 months in median from the age of ten), 40 (6.1%) died and 85 (13.1%) were lost-to-follow-up (Table 2). The median age at the endpoint was 13.1 years.

Overall, 187 (29.8%) adolescents knew their HIV status (Table 3). Compared to those not disclosed, adolescents with disclosed HIV status were, at ART initiation:

- Older (median age: 11.9 vs 9.8 years, p<0.0001)
- More often on NNRTI-based ART (76.5% vs. 65.6%, p = 0.007)
- Less often living with their parents (45.9% vs. 57.0%, p = 0.011)

The year of disclosure was known for only 59 adolescents (31.5%) (Table 3). This variable was poorly reported in the charts in Abidjan. When known, the median age at disclosure was 15 years (IQR: 14–15; min = 11; max = 19). At the time of disclosure or end point, 471 adolescents (72.5%) were known to be orphaned of at least one parent (biological mother or father) and 330 (50.8%) were known to live at that time with a parent.

Conditions of the disclosure of the HIV status to the adolescents

Most of HIV disclosures happened after ART initiation and were planned (Table 4). The persons involved in this process varied across the countries. It was mainly conducted by the family, particularly the mother and the father in Abidjan after an interview between the latter and the psychologists, while it was conducted by the health care staff in Bamako and Dakar.
Effect of the adolescents’ knowledge of their HIV status on retention in care

The overall 36-month probability of retention after ART initiation in this sample aged ≥10 was 74.6% (95% CI: 70.5–79.0). It was significantly lower for those whose HIV status was not disclosed (Figure 2). Overall, the 3-year probability of survival was 92.1% (95% CI: 89.4–95.0) and the probability of not being lost-to-follow-up was 80.4% (95% CI: 76.5–84.5). Disclosed HIV status was associated with higher retention in care in multivariate analysis: adjusted hazard ratio (aHR) = 0.23 (95% CI: 0.13–0.39; p < 0.0001) (Table 5).

Description of excluded patients with MD on disclosure and sensitivity analysis

There were 19 adolescents excluded because of MD on disclosure status (17 from Abidjan). Three were dead and five lost to follow-up by 31 months in median after ART initiation after the age of ten.

If all patients with missing data were classified as not-disclosed HIV status, the probability of retention for these patients decreased to 60.8% (95%CI 55.2–67.1), increasing the difference according to the HIV disclosure status. If all patients with missing data were classified as disclosed HIV positive status, the probability of retention for these patients increased to 89.7% (95%CI 84.4–93.9), decreasing the difference between the two groups but it remained statistically significant, in univariate and multivariate analyses (aHR = 0.28; 95%CI = 0.18–0.44).

Discussion

In this multicentered cohort study conducted in West Africa, we described a large sample of HIV-infected adolescents who started ART at a median age of 10.4 years. Despite this information was not documented with reliability in this cohort, it is estimated that more than 90% of the children/adolescents acquired HIV through mother-to-child transmission and can be considered as slow progressors [27]. We observed that about two thirds of HIV-infected adolescents on ART beyond the age of ten were not aware of their own HIV status. When the age at disclosure was known, it was delayed around a median of 15 years. We demonstrated a beneficial effect of HIV disclosure on retention in care among adolescents on ART.

Although low, the frequency of disclosed HIV status in our study was higher than previously reported figures in studies conducted in Nigeria, Ethiopia, Thailand and India where the children were younger (mean age = 8–9 years) [13,17,18,28] or Ghana, with a median age of ten [12]. It was similar to other studies conducted in Uganda and Zambia in children aged 12 in median [4,11] or Thailand (mean age 9.2 years) [15] but a bit

Table 1. Characteristics of adolescents at ART initiation.

| Variable          | Unit   | Abidjan (n = 403) | Bamako (n = 174) | Dakar (n = 73) | Overall (n = 650) |
|-------------------|--------|------------------|-----------------|---------------|------------------|
|                   |        | N Med (IQR)      | N Med (IQR)     | N Med (IQR)   | N Med (IQR)      |
| Age               | Years  | 402 10.7 (8.8–12.8) | 174 10.0 (8.4–11.7) | 73 9.9 (8.7–13.0) | 650 10.4 (8.8–12.7) |
| CD4 cells/mm³     |        | 363 283 (78–529)  | 173 171 (57–325) | 46 121 (19–350) | 582 224 (63–424)  |
| Haemoglobin g/dL  |        | 356 10.2 (9.0–11.1) | 161 9.7 (8.7–10.7) | 40 9.0 (7.7–11.0) | 557 10 (8.7–11)   |
| Weight kg         |        | 357 24 (19–29)    | 155 20 (17–25)   | 69 21 (18–27)  | 581 23 (19–27)    |
| Stage 3&4/C       | N n (%)| 350 107 (30.6)    | 155 106 (68.4)   | 72 64 (88.9)  | 577 277 (48.0)    |
| NNRTI             | N n (%)| 403 271 (67.2)    | 174 118 (67.8)   | 73 58 (79.5)  | 650 447 (68.8)    |

Pediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral treatment; NNRTI: non nucleoside reverse transcriptase inhibitor; N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.
doi:10.1371/journal.pone.0033690.t001

Table 2. Follow-up characteristics of adolescents on ART.

| Variable                            | Unit       | Abidjan (n = 403) | Bamako (n = 174) | Dakar (n = 73) | Overall (n = 650) |
|-------------------------------------|------------|------------------|-----------------|---------------|------------------|
|                                    |            | Med (IQR)        | Med (IQR)       | Med (IQR)     | Med (IQR)        |
| Follow-up from ART initiation       | Months     | 36.5 (23.6–38.6) | 29.1 (16.6–52.1) | 45.8 (24.3–67.0) | 35.8 (21.2–39.8) |
| Follow-up from the age of 10        | Months     | 24.3 (12.5–36.5) | 19.0 (9.8–31.6) | 25.4 (14.2–49.0) | 23.3 (11.3–36.6) |
| Age at endpoint                     | Years      | 13.3 (11.5–15.3) | 12.5 (11.2–14.5) | 13.8 (11.7–16.5) | 13.1 (11.5–15.3) |
| Death n (%)                         |            | 19 (4.7)         | 10 (5.7)        | 11 (15.0)     | 40 (8.1)         |
| Mortality incidence from the age of 10 /1000 pers-month | 1.97 | 2.51 | 4.49 | 2.49 |
| Loss-to-follow-up n (%)             |            | 45 (11.2)        | 35 (20.1)       | 5 (6.8)       | 85 (13.1)        |

Pediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral therapy.
N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.
doi:10.1371/journal.pone.0033690.t002
lower than an Ivorian study involving adolescents older than 13 years [19]. Indeed, disclosure was often associated with an age >10 or even older [13,17,18,29,30], supporting our observations. In a qualitative study conducted in South Africa, the age of ten has been reported by health workers as the most appropriate to start having discussion regarding HIV infection [31].

In a US perinatally HIV-infected cohort, HIV disclosure was observed to occur at younger age over time, which may suggest a decline in the perception of HIV stigma [29]. In this industrialized country, the social and medical network may have been strengthened, leading to this condition. In resource-limited settings, despite local interventions, such as peer support groups, or community organizations for social support, stigma and fear of negative reactions or psychosocial outcomes may remain strong barriers to an earlier HIV disclosure to children [4,12,15,17,22,32,33,34,35]. Conditions of disclosure varied according to settings. In Abidjan, relatives were encouraged to conduct the disclosure while the medico-social staff was more involved in the other countries. In Nigeria, most of the disclosure was conducted by family, preferably the mother, at home [18]. In Ghana, it was also mostly conducted by caregivers [12], but among those who had not disclosed, one-third wanted to defer to the health workers. Similarly, in Ethiopia, 60% of 193 caregivers interviewed thought that the doctor was responsible for disclosure [17] and in Thailand, 50% of the interviewed caregivers reported the need of assistance from health workers [15].

### Table 3. Characteristics of adolescents at HIV disclosure or last contact.

| Variable                        | Abidjan (n = 403) | Bamako (n = 174) | Dakar (n = 73) | Overall (n = 650) |
|---------------------------------|-------------------|------------------|---------------|------------------|
|                                 | n (%))            | n (%))           | n (%))        | n (%)            |
| Disclosure                      | Yes 127 (31.5)    | 44 (25.3)        | 16 (21.9)     | 187 (28.8)       |
| Known date of disclosure        | Yes 10/127 (7.9)  | 40/44 (90.9)     | 9/16 (56.2)   | 59/187 (31.5)    |
| Orphanhood                      | No 98 (24.3)      | 38 (21.8)        | 14 (19.2)     | 150 (23.1)       |
| One parent                      | 187 (46.4)        | 61 (35.1)        | 35 (47.9)     | 283 (43.5)       |
| Two parents                     | 100 (24.8)        | 67 (38.5)        | 21 (28.8)     | 188 (28.9)       |
| Unknown                         | 18 (4.3)          | 8 (4.6)          | 3 (4.1)       | 29 (4.5)         |
| Living with parents             | No 162 (40.2)     | 84 (48.3)        | 36 (49.3)     | 282 (43.4)       |
| Yes 208 (51.6)                  | 86 (49.4)         | 36 (59.3)        | 330 (50.8)    |
| Unknown                         | 33 (8.2)          | 4 (2.3)          | 1 (1.4)       | 38 (5.8)         |
| Schooling                       | No 54 (13.4)      | 31 (17.8)        | 26 (35.6)     | 111 (17.1)       |
| Yes 319 (79.2)                  | 108 (62.1)        | 43 (58.9)        | 470 (72.3)    |
| Unknown                         | 30 (7.4)          | 35 (20.1)        | 4 (5.5)       | 69 (10.6)        |

Piediatric IeDEA West Africa (WADA) Collaboration.
N: number.
doi:10.1371/journal.pone.0033690.t003

### Table 4. Characteristics of the process of HIV disclosure of adolescents.

| Variable                          | Abidjan (n = 127) | Bamako (n = 44) | Dakar (n = 16) | Overall (n = 187) |
|-----------------------------------|-------------------|-----------------|---------------|------------------|
|                                   | n (%))            | n (%))          | n (%))        | n (%)            |
| Mother involved in disclosure     | 35 (27.6)         | 0 (0)           | 0 (0)         | 35 (18.7)        |
| Father involved in disclosure     | 26 (20.5)         | 1 (2.3)         | 0 (0)         | 27 (14.4)        |
| Physician involved in disclosure  | 4 (3.1)           | 40 (90.9)       | 8 (50.0)      | 52 (27.8)        |
| Psychologist involved in disclosure | 6 (4.7)          | 0 (0)           | 3 (18.7)      | 9 (4.8)          |
| Social worker/counsellor involved in disclosure | 1 (0.8)      | 0 (0)           | 5 (31.2)      | 6 (3.2)          |
| Conditions of the disclosure      | 62 (48.8)         | 5 (11.4)        | 2 (12.5)      | 69 (36.9)        |
| Planned                           | 67 (52.8)         | 40 (90.9)       | 9 (56.2)      | 116 (62.0)       |
| Not planned                       | 55 (43.1)         | 0 (0)           | 5 (31.2)      | 60 (32.1)        |
| Not known                         | 5 (3.9)           | 4 (9.1)         | 2 (12.5)      | 11 (5.9)         |
| Timing of disclosure              | 10 (7.9)          | 0 (0)           | 2 (12.5)      | 12 (6.4)         |
| Before ART initiation             | 107 (84.2)        | 40 (90.9)       | 13 (81.2)     | 160 (85.6)       |
| After ART initiation              | 10 (7.9)          | 4 (9.1)         | 1 (6.2)       | 15 (8.0)         |

Piediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral therapy.
*Consisted in other persons of the family (uncle, aunt, grand-mother, grand-father, adoptive father or mother), persons from foster care shelters or NGOs (n = 14), nobody involved because of reading the notice (n = 4).
doi:10.1371/journal.pone.0033690.t004
Figure 2. Probability of retention in HIV care while on antiretroviral therapy (ART) according to disclosed HIV status taking into account the delayed entry at age of 10 years (n = 650). Pediatric iDEA West Africa Collaboration. * Estimation at 36 months from ART initiation.
doi:10.1371/journal.pone.0033690.g002

Table 5. Crude and adjusted hazard ratios (HR) with 95% confidence intervals (CI) of risk of death or loss-to-follow-up of adolescents after ART initiation (n = 650).

| Variables                          | Crude          | Adjusted       |
|-----------------------------------|----------------|----------------|
|                                   | HR  | 95%CI   | p-value  | aHR | 95%CI | p-value |
| Disclosure (ref: no)              | Yes | 0.23   | 0.13–0.39  | <0.0001 | 0.23 | 0.13–0.39 | <0.0001 |
| Gender                            | Male | 1.08 | 0.76–1.55 | 0.655 |
| CD4<200 cells/mm³ (ref: no)       | Yes | 1.73 | 1.17–2.55 | 0.014 | 1.65 | 1.11–2.44 | 0.017 |
|                                    | MD  | 1.75 | 0.99–3.08 | 1.97 | 1.07–3.62 |
| Severe anaemia (ref: no)          | Yes | 0.74 | 0.27–2.01 | 0.363 |
|                                    | MD  | 1.34 | 0.84–2.01 |
| NNRTI- based regimen (ref: no)    | Yes | 0.87 | 0.84–1.13 | 0.461 |
| Stage 3/4/C (ref: no)             | Yes | 1.29 | 0.88–1.88 | 0.405 |
|                                    | MD  | 1.07 | 0.57–2.02 |
| Country (ref: Côte d’Ivoire)      | Mali | 1.78 | 1.19–2.66 | 0.014 | 1.74 | 1.15–2.64 | 0.016 |
|                                    | Sénégal | 1.09 | 0.62–1.93 | 0.87 | 0.48–1.57 |

Pediatric iDEA West Africa Collaboration.
All analyses used the center as a cluster variable, taking into account the correlation of the observations within a same center.
HR: Hazard ratio.
aHR: adjusted hazard ratio.
MD: missing data.
ART: Antiretroviral therapy.
NNRTI: non nucleoside reverse transcriptase inhibitor.
Severe anemia: haemoglobin ≤6.9 g/dL.
Severe immunosuppression: CD4<200 cells/mm³.
doi:10.1371/journal.pone.0033690.t005
supported by a study on health workers’ perceptions conducted in a South African setting [31]. In this present study, the sites implemented different strategies to conduct the disclosure process (described in the Methods), which could explain, in part, the differences observed between across the cities in terms of retention. Also, the investigators of the participating centers were aware of the recommendations from the French-speaking association called Grandir [36,37]. However, they faced difficulties not addressed by these recommendations. For instance, they had problems to manage the caregivers’ reluctance to disclose or to make understand to the adolescent what HIV is and its impact on life. They required sharing field experiences to harmonize process and guide local policy on HIV disclosure to be conducted in optimal conditions involving both adolescents and their caregivers. Recent guidelines proposed by the World Health Organization underlined the absence of evidence as to who best can disclose to the child his/her HIV status, caregiver or World Health Organization underlined the absence of evidence as to adolescents and their caregivers. Recent guidelines proposed by the World Health Organization underlined the absence of evidence as to who best can disclose to the child his/her HIV status, caregiver or health care worker with or without specific training [38].

In this large cohort with three-year follow-up, we observed a relatively low death rate but a quite important loss-to-follow up rate, similar to a previous report on clinical outcomes in West African children [25]. In a study conducted in Uganda, including 375 patients starting ART during adolescence, the cumulative survival at 36 months was 90% (95% CI 87.9–93.1) [39]. This figure was similar to the survival rate found in our study where 55% has initiated ART after the age of ten. We found that HIV disclosure was associated with better retention in care as already reported in a Romanian setting among adolescents with a mean age of 13 years [40].

Several limitations could be discussed in our study. First, the main limit of this study is its partially retrospective design and the fact that it relied heavily on the patients’ charts, leading to missing data and possible information bias. In particular, the HIV disclosure status was not systematically reported in the patients’ charts. However, the forms were filled in by clinic staff, who knew the patients and their family environment quite well and could remember and cross-check who was informed of his/her HIV status and who was not. Some charts could not be found or used and were classified as missing data and the corresponding adolescents were not included in the analyses. Sensitivity analyses, coding these records either as disclosed HIV status or not disclosed did not lead to a large variation in our findings.

Second, the HIV disclosure status was reported as a dichotomous variable, while disclosure is a process evolving over time. Thus some adolescents may have been categorized as not informed of their HIV status while they may have been told that they harbour a virus, but not specifying HIV. Some studies, preferably those with a qualitative design, specify that some children are partially disclosed. It refers to the following broad category: “child not fully aware of his/her HIV disease but is suspicious, asks questions to the caregiver about the disease and the drug, and, in many cases, assumes that the drug is a cure” [11]. This status could not have been taken into account in our study with no qualitative data recorded. In addition, the age at disclosure was frequently missing and it was not possible to study this variable as a time-dependant information in the survival analyses.

Third, some of the adolescent lost-to-follow-up might have been unreported deaths. We have addressed this possible misclassification by specifically retrieving and reviewing every patient’s chart meeting the definition of loss-to-follow-up in case the charts had been completed after the closure of the database for this analysis.

Finally, due to the retrospective design, we could not address the psychosocial effect of disclosure. A cross-sectional study conducted in New York City demonstrated that Youths (n = 196, mean age 12.7 years) with disclosed HIV status were significantly less anxious than those who had not been told but there were no other differences in psychological functioning [30]. This should be verified in African settings as the caregivers’ fear for negative psychosocial outcomes is a common barrier to disclose as discussed previously.

In conclusion, most of HIV-infected adolescents on ART in these West African settings were not aware of their HIV status. However, our study showed a stronger beneficial effect of HIV disclosure on retention in care after ART initiation beyond the age of ten. This sample of clinics had initiated different strategies to carry out the HIV disclosure process in the absence of guidelines or specific training. Such initiatives need to be promoted and developed as they may provide individual benefits. For this purpose, they need to be described, standardized, evaluated and shared. Also, further studies should look at the effect on other outcomes such as immunological failure, treatment adherence, virological progression, viral resistance, but also anxiety, depression, school performance, family and social relations and sexual risk behaviours. This would provide deeper understanding of HIV disclosure process in adolescents in resource limited settings in order to tailor age-adequate interventions.

Acknowledgments

We acknowledge for their data management support Magloire Moh, Charles Anzan, Mr. Mamadou Kone and Karen Malateste.

We also acknowledge all of the children and families followed up in the participating pediatric centers. The International epidemiological Database to Evaluate AIDS in West Africa (IeDEA West Africa) is supported by: The National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (grant no. 5U01AI069919-01 to 05). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.

The study was presented in part at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, February 27–March 2, 2011; Poster S-142.

*The IeDEA West Africa pediatric working Group is constituted as follows:*

IeDEA West Africa primary investigators: Prof. F. Dahia (INSERM U389, ISPED, Bordeaux, France), Prof. E. Bissagnene (SMIT, CHU de Treichville, Abidjan, Côte d’Ivoire)

Clinical pediatric centers and investigators

- Benin, Cotonou: Centre National Hospitalo-Universitaire: Prof. S. Kounmakpi, Hôpital d’Instruction des Armées: Dr. A. Azondékon.
- Burkina Faso: Centre Hospitalier Charles de Gaulle, Prof. Y. Be Djarra, Dr. Flav-Kouesta.
- Côte d’Ivoire, CEPREF, Abdijan: Dr. A. Aka, Dr. E. Messou;
- MTCT Plus Network, Abdijan: Dr. P. Touré, Dr. C. Amani-Bosse; CHU de Yopougon, Abidjan: Dr. F.E. Tanoh, Prof. M. Timité-Konan; CIRBA, Abdijan: Dr. K. Kouakou.
- Gambia, Medical Research Council, Fajara: Dr. K. Peterson.
- Ghana, Korle Bu Hospital, Accra: Dr. L. Renner, Dr. B. Goka.
- Senegal, Hôpital d’Enfants Albert-Royer, Dakar: Prof. H. Signatay Sy, Dr. F. Ly Ndaye.
- Mali, Hôpital Gabriel Touré, Bamako: Prof. M. Sylla, Dr. F. Dicko, Dr. H. Traoré.
- Buréda G, ISPED staff: Dr. X. Anglatet, Dr. E. Arrive, Mr. E. Balestre, Mrs. A. Doring, Dr. D.K. Ekonovi, Dr. A. Jauget, Dr. V. Leroy, Dr. C. Lewedon, Mrs. K. Malateste, Mrs. E. Rabourdin, Dr. R. Thieubat, Dr. A. Sasco.
- Also, the investigators of the participating centers were aware of the recommendations from the French-speaking association called Grandir [36,37].
- The study was presented in part at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, February 27–March 2, 2011; Poster S-142.

Author Contributions

Conceived and designed the experiments: EA HA FD AEA PO HADA AA FD VL. Performed the experiments: HA FD AEA PO HADA AA FD VL. Performed the experiments: HA FD AEA PO HADA AA FD VL. Analyzed the data: AA EA. Wrote the paper: EA FD DKE VL.
References

1. Foster C, Fidler S (2010) Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti Infect Ther 8: 1403–1416.

2. UNAIDS (2011) Global HIV response. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf. Accessed February 10, 2012.

3. Musini R, Kinyanda E (2009) Emotional and behavioural disorders in HIV seropositive adolescents in urban Uganda. East Afr Med J 86: 16–24.

4. Mennon A, Glazebrook C, Campain N, Ngoma M (2007) Mental health and disclosure of HIV status in Zambian adolescents with HIV infection: implications for peer-support programs. J Acquir Immune Defic Syndr 46: 349–354.

5. Nachega JB, Hidrop M, Nguyen H, Dowdy DW, Chaisson RE, et al. (2009) Antiretroviral therapy adherence, virologic and immunological outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 51: 65–71.

6. Ryscavage PA, Anderson EJ, Sutton SH, Reddy S, Taiwo B (2011) Clinical Outcomes of Adolescents and Young Adults in HIV Care. J Acquir Immune Defic Syndr 59: 628–633.

7. Charles M, Noel F, Leger P, Severe P, Riviere C, et al. (2006) Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 84: 970–977.

8. Ding H, Wilson CM, Modjarrad K, McGivin G, Jr., Tang J, et al. (2009) Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project. Arch Pediatr Adolesc Med 163: 1100–1105.

9. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J (2009) Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a prevalence of interactions. AIDS Patient Care STDS 23: 183–194.

10. Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, et al. (2011) Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nonadherence, and paradoxical income effects. PLoS One 6: e15305.

11. Bikaako-Kajura W, Layirika E, Purcell DW, Downing J, Kaharuza F, et al. (2006) Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav 10: S85–93.

12. Kallem S, Renner L, Ghebremichael M, Parnail E (2011) Prevalence and Pattern of Disclosure of HIV Status in HIV-Infected Children in Ghana. AIDS Behav 13: 1121–1127.

13. Arun S, Singh AK, Lodha R, Kahra SK (2009) Disclosure of the HIV infection status in children. Indian J Pediatr 76: 805–808.

14. Bakeera-Kitaka S, Nabukwasa-Barungi N, Nostlinger C, Addy K, Colhouners R (2008) Sexual risk reduction needs of adolescents living with HIV in a clinical care setting. AIDS Care 20: 430–433.

15. Oberendorfer F, Puthanakit T, Louzehreno O, Charmil C, Sirisantana V, et al. (2006) Disclosure of HIV/AIDS diagnosis to HIV-infected children in Thailand. J Paediatr Child Health 42: 280–288.

16. Bhattacharya M, Dube AP, Sharma M (2010) Patterns of Diagnosis Disclosure and its Correlates in HIV-Infected North Indian Children. J Trop Pediatr Epub ahead of print.

17. Biadgilign S, Deribe B, Amherbir A, Escudero HB, Deribe K (2011) Factors associated with HIV/AIDS diagnostic disclosure to HIV infected children receiving HAART: a multi-center study in Addis Ababa, Ethiopia. PLoS One 6: e15772.

18. Brown BJ, Oladokun RE, Osimai K, Ochigbo S, Adesole IF, et al. (2011) Disclosure of HIV status to infected children in a Nigerian HIV Care Programme. AIDS Care. pp 1–6.

19. Meles D, A-D-A-H H, Cacou C, Aka A, Oga A, et al. Disclosure of HIV test results in HIV-infected adolescents in the Aconda program (CoPRoF, CHU Yopougon) in Abidjan, Côte d’Ivoire, The Project PRADO-CI, 2010 July 8-18- 2010; Vienna.

20. Foster C, Waelbroeck A, Peliter A (2007) Adolescents and HIV infection. Curr Opin HIV AIDS 2: 431–436.

21. Gray GE (2010) Adolescent HIV-cause for concern in Southern Africa. PLoS Med 7: e1000227.

22. Kupomba J, Mbasalakwambwa CL, Ndelozi G (2010) Challenges faced by health workers in providing counselling services to HIV-positive children in Uganda: a descriptive study. J Int AIDS Soc 13: 9.

23. De Baets AJ, Sifowo S, Parasomos R, Pazvakavambwa E (2008) HIV disclosure and discussions about grief with Shona children: A comparison between health care workers and community members in Eastern Zimbabwe (English). Social science & medicine (1982) 66: 479–491.

24. Moodley K, Myer L, Michaels D, Cotten M (2006) Paediatric HIV disclosure in South Africa – caregivers’ perspectives on discussing HIV with infected children. S Afr Med J 96: 201–204.

25. Elouevi DK, Azonoudek A, Dicko F, Malateste K, Toure P, et al. (2011) 12-month mortality and loss-to-program in antiretroviral-treated children: The iDeA pediatric West African Database to evaluate AIDS (pWADA), 2000–2008. BMC Public Health 11: e183.

26. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Available from: http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf. Accessed February 10, 2012.

27. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE, et al. (2009) AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 23: 2059–2066.

28. Boon-Yasidi V, Kottaput U, Durier Y, Pipat N, Phongsamart W, et al. (2005) Diagnosis disclosure in HIV-infected Thai children. J Med Assoc Thai 88 Suppl II: S100–105.

29. Butler AM, Williams PL, Howland LG, Storm D, Hutton N, et al. (2009) Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics 123: 935–943.

30. Santamaria EH, Deolalikar C, Marbecke SL, Hoffman S, Ahmed V, et al. (2011) Psychosocial implications of HIV serostatus disclosure to youth with perinatally acquired HIV. AIDS Patient Care STDS 25: 257–264.

31. Myer L, Moodley K, Hendricks F, Cotten M (2006) Healthcare providers’ perspectives on discussing HIV status with infected children. J Trop Pediatr 52: 293–295.

32. Yecp AD, Hamilton R, Charalampos S, Dzwadwa T, Churchyard GJ, et al. (2010) Factors influencing uptake of HIV care and treatment among children in South Africa - a qualitative study of caregivers and clinic staff (English). AIDS Care (Print) 22: 1101–1107.

33. Vreeman RC, Nyandiko WM, Ayaya SO, Wambuge EM, Marrero DG, et al. (2010) The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral adherence, child well-being, and social relationships in a resource-limited setting. AIDS Patient Care STDS 24: 639–649.

34. Vaz L, Corneli A, Dulyu J, Rennie S, Omba S, et al. (2008) The process of HIV status disclosure to HIV-positive youth in Kinshasa, Democratic Republic of the Congo. AIDS Care 20: 842–852.

35. Vaz LM, Maman S, Eng E, Barbarin OA, Tshikandu T, et al. (2011) Patterns of Disclosure of HIV Status to Infected Children in a Sub-Saharan African Setting. J Dev Behav Pediatr.

36. Grandir (2007) L’annonce de diagnostic d’infection à VIH à l’enfant : Pourquoi est-ce important ? Available from: http://www.grandir.sidaction.org/2-10-5/publications-grandir/fiches-pratiques.htm. Accessed February 10, 2012.

37. Grandir (2007) L’annonce de diagnostic d’infection à VIH à l’enfant : Qui, quand, comment ? Available from: http://www.grandir.sidaction.org/2-10-1/publications-grandir/fiches-pratiques.htm. Accessed February 10, 2012.

38. World Health Organization (2011) Guideline on HIV disclosure counselling for children up to 12 years of age. Available from: http://whqlibdoc.who.int/publications/2011/9789241502863_eng.pdf. Accessed February 10, 2012.

39. Bakanda C, Burungi J, Mweesiga R, Nachega JB, Chau K, et al. (2011) Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One 6: e19261.

40. Ferris M, Burau K, Schweitzer AM, Mihale S, Murray N, et al. (2007) The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care 19: 1608–1694.